A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem? An alarming number of patients prescribed Nerlynx -- ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...